Status:
ENROLLING_BY_INVITATION
Implementation of the Intravitreal Injection Administered by Nurses
Lead Sponsor:
Corporacion Parc Tauli
Conditions:
Macular Edema
Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
Introduction: Intravitreal injections involve medication administration into the eye to treat ocular diseases and protect vision. Through an injection, the medication is introduced into the vitreous ...
Eligibility Criteria
Inclusion
- Inclusion criteria
- \- People over 18 years of age who require intravitreal therapy in the ophthalmology service
- Exclusion criteria
- Non-collaborators in the technique for physical, psychological or nystagmus reasons.
- Have recent evidence of blepharitis or conjunctivitis ≤15 days (ex, red eye or thick discharge) to avoid the risk of introducing infection into the eyeball.
- Suffer ischemic heart disease or recent stroke ≤3 months to avoid the risk of precipitating another vascular ischemic attack.
- With intravitreal steroid implant.
- Pregnant women: Due to the potential teratogenic effect of anti-FCEV
Exclusion
Key Trial Info
Start Date :
January 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06511700
Start Date
January 15 2025
End Date
June 30 2026
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Corporation Parc Tauli
Sabadell, Barcelona, Spain, 08208